Asklepios BioPharmaceutical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asklepios BioPharmaceutical, Inc.
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Marianne De Backer, head of pharma BD and licensing at the German firm, told Scrip, "We strongly believe that the future is allogeneic and we were looking for pioneers in the field."
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Actus Therapeutics, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics